oxycodone has been researched along with Prostatic Neoplasms, Castration-Resistant in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benoist, GE; Cremers, RGHM; Detert Oude Weme, SEH; Hulskotte, LMG; Imholz, ALT; Jansman, FGA; Reyners, AKL; Taxis, K; van Berlo-van de Laar, IRF; Vervenne, WL | 1 |
| Gerritsen, WR; Kramers, C; Kuip, EJM; van Oort, IM; Vissers, KCP; Westdorp, H | 1 |
2 other study(ies) available for oxycodone and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
Topics: Analgesics, Opioid; Chromatography, Liquid; Humans; Male; Oxycodone; Oxymorphone; Pain; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Tandem Mass Spectrometry | 2023 |
Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer.
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents; Benzamides; Bone Neoplasms; Drug Interactions; Fentanyl; Humans; Male; Middle Aged; Nitriles; Oxycodone; Pain; Pain Management; Palliative Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant | 2018 |